Tiziana–Novimmune: therapeutic antibody, 201412– license to foralumab (NI-0401) to Tiziana

	Period	2014-12-01
	Successor	Tiziana–Novimmune: therapeutic antibody, 201701– license excl €na to develop + commercialise anti-IL-6R MAb NI-1201
	Partner, 1st	Tiziana Life Sciences plc (AIM: TILS, Nasdaq: TLSA)
	Partner, 2nd	Novimmune S.A.
	Product	foralumab (NI-0401)
	Product 2	drug development

Novimmune S.A.. (1/4/17). "Press Release: Novimmune Grants Tiziana an Exclusive License to NI-1201, an anti-IL-6R Monoclonal Antibody for the Treatment of Autoimmune and Inflammatory Diseases". Geneva.

Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs, and Tiziana Life Sciences (TILS), have signed a second collaboration agreement granting Tiziana exclusive rights to develop and commercialize its anti-IL-6R monoclonal antibody, NI-1201.

Anti-IL6R antibodies are marketed or in development for a range of inflammatory conditions including rheumatoid arthritis. Tiziana intends to explore the development of NI-1201 in Non-alcoholic Steato hepatitis (NASH), diabetes and other life threatening inflammatory diseases, as well as foralumab (NI-0401), the first antibody that Novimmune licensed to Tiziana in December 2014. Financial details were not disclosed.

“Two years ago, we entered into our first collaboration with Tiziana and we have been very pleased with the progress they have made with NI-0401, currently in phase 2 clinical development. We are delighted to have signed this second agreement to move NI-1201 forward, and we believe this is a very exciting molecule which complements Tiziana’s portfolio.” said Novimmune Chairman and Chief Executive Officer, Eduard Holdener.

About Novimmune

Novimmune SA is a privately held, Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva and currently employs 122 people. More information is available on the company website at www.novimmune.com.

Contact:

Adrian Mills
+41 (0) 61 201 13 27
amills@novimmune.com